Li-Fraumeni syndrome: cancer risk assessment and clinical management

Kate A. McBride(The University of Sydney), Gillian Mitchell(Peter MacCallum Cancer Centre), Mandy L. Ballinger(Garvan Institute of Medical Research), Emma Killick(Institute of Cancer Research), Judy Kirk(The University of Sydney), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Martin H.N. Tattersall(Royal Prince Alfred Hospital), David M. Thomas(New South Wales Department of Health)
Nature Reviews Clinical Oncology
March 18, 2014
10.1038/nrclinonc.2014.41
Cited by 276

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k